# Agilent Technologies

> Agilent Technologies supplies analytical and clinical laboratories with instruments, software, consumables, reagents, and services. An HP spin-off listed on the NYSE as A, it serves pharmaceutical, diagnostic, research, food, environmental, and materials laboratories worldwide; fiscal 2025 revenue was $6.948 billion.

- **Founded:** 1999
- **Headquarters:** Santa Clara, United States
- **Founders:** Hewlett-Packard Company (Originating parent company; Agilent was created as an HP spin-off, not a separately founded startup)
- **Products:** Infinity III LC Series, Gas chromatography and mass spectrometry, Agilent CrossLab, OpenLab CDS, Seahorse XF
- **Notable:** Raised US$2.1 billion in its November 1999 IPO., Separated its electronic measurement business as Keysight in November 2014., PD-L1 IHC 22C3 pharmDx received initial FDA approval in 2015.

## Products & services

- **Infinity III LC Series** — Liquid chromatography systems launched in October 2024, including 1290, 1260 Prime, and 1260 models, with InfinityLab Assist automation and guided operation.
- **Gas chromatography and mass spectrometry** — Systems that separate, identify, and quantify compounds in pharmaceutical, environmental, food, and materials applications.
- **Agilent CrossLab** — Consumables and laboratory services including repair, preventive maintenance, compliance, relocation, and support for eligible instruments from other manufacturers.
- **OpenLab CDS** — Chromatography data software supporting instrument control, data analysis, and data-integrity workflows, including supported third-party instruments.
- **Seahorse XF** — Cell-metabolism analyzers and assays measuring oxygen consumption and extracellular acidification. Agilent acquired Seahorse in 2015.
- **BioTek** — Microplate readers and cell-imaging systems added through the 2019 acquisition.
- **Dako and pharmDx** — Pathology instruments, antibodies, reagents, and companion diagnostic assays, including PD-L1 IHC 22C3 pharmDx.
- **Genomics and biomolecular analysis** — Sample preparation, nucleic-acid quality control, microarrays, and other tools supporting genomics workflows.
- **Contract development and manufacturing** — Nucleic-acid manufacturing services and BIOVECTRA capabilities in biologics, potent active ingredients, and targeted therapeutics.
- **Biocare Medical** — Clinical and research pathology antibodies, reagents, and instruments; acquisition completed June 25, 2026.

## Achievements

- Raised US$2.1 billion in its November 1999 IPO.
- Separated its electronic measurement business as Keysight in November 2014.
- PD-L1 IHC 22C3 pharmDx received initial FDA approval in 2015.
- Fiscal 2025 revenue reached US$6.948 billion.
- Reported fiscal Q3 2026 revenue of US$1.878 billion, up 8.1% year over year.

## Latest updates

- **2026-10** — October 13: announced an agreement to acquire Proscia for $240 million cash at closing plus up to $30 million in performance milestones; announcement is not proof of closing.
- **2026-08** — August 26: reported fiscal Q3 revenue of $1.878 billion and raised fiscal 2026 revenue guidance to $7.49-$7.51 billion.
- **2026-06** — June 25: completed the Biocare Medical acquisition, previously announced at $950 million.

## Links

- Website: https://www.agilent.com/
- LinkedIn: https://www.linkedin.com/company/agilent-technologies/
- Twitter/X: https://twitter.com/agilent
- YouTube: https://www.youtube.com/agilent
- Instagram: https://www.instagram.com/agilenttechnologies/
- Facebook: https://www.facebook.com/Agilent.Tech

---

Profile page: https://yespress.io/agilent-technologies
Published by YesPress — https://yespress.io
Last updated: 2026-10-22